New drug trial aims to protect transplanted kidneys
NCT ID NCT05156710
Summary
This study is testing an investigational drug called BIVV020 to see if it can help prevent or treat a serious complication called antibody-mediated rejection in adults who have received a kidney transplant. The trial will enroll 48 participants who are either about to receive a transplant or have recently been diagnosed with this type of rejection. Researchers will compare the effects of BIVV020 plus standard care against standard care alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSPLANT REJECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham & Women's Hospital- Site Number : 8400004
Boston, Massachusetts, 02115, United States
-
Cedars-Sinai Medical Center- Site Number : 8400100
Los Angeles, California, 90048, United States
-
Investigational Site Number : 1240001
Vancouver, British Columbia, V6Z 1Y6, Canada
-
Investigational Site Number : 1240002
London, Ontario, N6A 5A5, Canada
-
Investigational Site Number : 1240003
Montreal, Quebec, H4A 3J1, Canada
-
Investigational Site Number : 1240101
Vancouver, British Columbia, V5Z 1M9, Canada
-
Investigational Site Number : 2500001
Paris, 75010, France
-
Investigational Site Number : 2500002
Créteil, 94010, France
-
Investigational Site Number : 2500005
Toulouse, 31059, France
-
Investigational Site Number : 2500007
Bordeaux, 33076, France
-
Investigational Site Number : 2760001
Munich, 81675, Germany
-
Investigational Site Number : 2760002
Berlin, 13353, Germany
-
Investigational Site Number : 2760004
Essen, 45147, Germany
-
Investigational Site Number : 3800001
Brescia, Lombardy, 25123, Italy
-
Investigational Site Number : 3800002
Rome, Lazio, 00168, Italy
-
Investigational Site Number : 3800003
Milan, Milano, 20162, Italy
-
Investigational Site Number : 3800004
Bologna, Emilia-Romagna, 40138, Italy
-
Investigational Site Number : 7240002
Madrid, Madrid, Comunidad de, 28046, Spain
-
Investigational Site Number : 7240003
Madrid, Madrid, Comunidad de, 28041, Spain
-
Investigational Site Number : 7240004
Barcelona, Barcelona [Barcelona], 08035, Spain
-
Investigational Site Number : 7520001
Huddinge, 141 57, Sweden
-
Investigational Site Number : 7520002
Uppsala, 751 85, Sweden
-
Massachusetts General Hospital- Site Number : 8400007
Boston, Massachusetts, 02114, United States
-
NYU Langone Medical Center- Site Number : 8400102
New York, New York, 10016, United States
-
University of California Los Angeles Medical Center- Site Number : 8400103
Los Angeles, California, 90095, United States
-
University of California San Francisco - Parnassus Heights- Site Number : 8400001
San Francisco, California, 94143, United States
-
University of Wisconsin Hospitals and Clinics- Site Number : 8400003
Madison, Wisconsin, 53792, United States
Conditions
Explore the condition pages connected to this study.